XML 60 R48.htm IDEA: XBRL DOCUMENT v3.25.3
Segment and Geographic Data (Sales And Other Financial Information By Business Segment) (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     2  
Segment Reporting Information [Line Items]        
Number of reportable segments | segment     2  
Net sales $ 6,057 $ 5,494 $ 17,945 $ 16,159
Reclassification to: cost of sales 2,205 1,977 6,508 5,893
Research, development and engineering expenses 410 377 1,222 1,108
Selling, general and administrative expenses 2,045 1,894 6,424 5,562
Depreciation and amortization 404 371 1,154 1,080
Amortization of intangible assets (189) (159) (543) (467)
Segment operating income 1,135 1,085 3,085 3,108
Goodwill and other impairments (73) (2) (163) (21)
Net earnings 859 834 2,397 2,447
MedSurg and Neurotechnology:        
Segment Reporting Information [Line Items]        
Net sales 3,803 3,324    
Operating Segments        
Segment Reporting Information [Line Items]        
Net sales 6,057 5,494 17,945 16,159
Reclassification to: cost of sales 2,046 1,874 6,010 5,566
Research, development and engineering expenses 379 341 1,117 1,000
Selling, general and administrative expenses 1,714 1,540 5,225 4,585
Depreciation and amortization 167 172 484 495
Amortization of intangible assets (189) (159) (543) (467)
Segment operating income 1,751 1,567 5,109 4,513
Operating Segments | MedSurg and Neurotechnology:        
Segment Reporting Information [Line Items]        
Net sales 3,803 3,324 11,085 9,636
Reclassification to: cost of sales 1,426 1,313 4,162 3,838
Research, development and engineering expenses 247 205 718 594
Selling, general and administrative expenses 972 780 2,893 2,318
Depreciation and amortization 56 60 171 170
Segment operating income 1,102 966 3,141 2,716
Operating Segments | Orthopaedics        
Segment Reporting Information [Line Items]        
Net sales 2,254 2,170 6,860 6,523
Reclassification to: cost of sales 620 561 1,848 1,728
Research, development and engineering expenses 132 136 399 406
Selling, general and administrative expenses 742 760 2,332 2,267
Depreciation and amortization 111 112 313 325
Segment operating income 649 601 1,968 1,797
Segment Reporting, Reconciling Item, Corporate Nonsegment        
Segment Reporting Information [Line Items]        
Depreciation and amortization 48 40 127 118
Segment operating income (202) (211) (670) (676)
Segment Reconciling Items        
Segment Reporting Information [Line Items]        
Sale of inventory stepped up to fair value at acquisition (61) (29) (160) (38)
Acquisition and integration-related charges (39) (48) (302) (49)
Structural optimization and other special charges (41) (22) (93) (92)
Goodwill and other impairments (73) (2) (163) (21)
Medical device regulation (11) (13) (30) (41)
Recall-related matters (1) 0 (56) (22)
Regulatory and legal matters 0 1 (7) 1
Net earnings $ 1,134 $ 1,084 $ 3,085 $ 3,108